Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011

Psychiatric Services

Volumn 66, Issue 6, 2015, Pages 604-609

  Connolly, John G ^a   Toomey, Timothy J ^a   Schneeweiss, Maria C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; HEMOGLOBIN A1C; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; QUETIAPINE; THIAZOLE DERIVATIVE;

ADJUSTMENT DISORDER; ADULT; AFFECTIVE PSYCHOSIS; ARTICLE; CHILD; DATA BASE; DEPRESSION; DRUG USE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HYPERKINESIA; JUVENILE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; NEUROSIS; PERSONALITY DISORDER; PHYSICAL STRESS; PRACTICE GUIDELINE; PRESCHOOL CHILD; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; ADOLESCENT; AFFECTIVE DISORDERS, PSYCHOTIC; ANXIETY DISORDERS; CHEMICALLY INDUCED; CLINICAL PRACTICE; COHORT ANALYSIS; CONDUCT DISORDER; DEPRESSIVE DISORDER; DIABETES MELLITUS; FACTUAL DATABASE; FEMALE; HYPERKINESIS; MALE; MASS SCREENING; MENTAL DISORDERS; METABOLISM; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; AFFECTIVE DISORDERS, PSYCHOTIC; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; ARIPIPRAZOLE; BENZODIAZEPINES; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONDUCT DISORDER; DATABASES, FACTUAL; DEPRESSIVE DISORDER; DIABETES MELLITUS; FEMALE; GUIDELINE ADHERENCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERKINESIS; MALE; MASS SCREENING; MENTAL DISORDERS; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PSYCHOTIC DISORDERS; QUETIAPINE FUMARATE; RETROSPECTIVE STUDIES; RISPERIDONE; THIAZOLES;

EID: 84930826997     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201400222     Document Type: Article

References (40)

1. Chaggar PS, Shaw SM, Williams SG: Effect of antipsychotic medications on glucose and lipid levels. Journal of Clinical Pharmacology 51:631-638, 2011
2. Hammerman A, Dreiher J, Klang SH, et al: Antipsychotics and diabetes: an age-related association. Annals of Pharmacotherapy 42:1316-1322, 2008
3. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(suppl 1):1-93, 2005
4. Vitiello B, Correll C, van Zwieten-Boot B, et al: Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. European Neuropsychopharmacology 19:629-635, 2009
5. Bobo WV, Cooper WO, Stein CM, et al: Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 70:1067-1075, 2013
6. Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 45:771-791, 2006
7. De Hert M, Dobbelaere M, Sheridan EM, et al: Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry 26:144-158, 2011
8. Arango C, Robles O, Parellada M, et al: Olanzapine compared to quetiapine in adolescents with a first psychotic episode. European Child and Adolescent Psychiatry 18:418-428, 2009
9. Correll CU, Manu P, Olshanskiy V, et al: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009
10. Maayan L, Correll CU: Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology 21:517-535, 2011
11. McIntyre RS, Jerrell JM: Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Archives of Pediatrics and Adolescent Medicine 162:929-935, 2008
12. Aparasu RR, Bhatara V: Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Current Medical Research and Opinion 23:49-56, 2007
13. Olfson M, Blanco C, Liu SM, et al: National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Archives of General Psychiatry 69:1247-1256, 2012
14. Gillberg C: Typical neuroleptics in child and adolescent psychiatry. European Child and Adolescent Psychiatry 9(suppl 1):I2-I8, 2000
15. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
16. Mitchell AJ, Delaffon V, Vancampfort D, et al: Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychological Medicine 42:125-147, 2012
17. Morrato EH, Newcomer JW, Allen RR, et al: Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. Journal of Clinical Psychiatry 69:316-322, 2008
18. Haupt DW, Rosenblatt LC, Kim E, et al: Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. American Journal of Psychiatry 166:345-353, 2009
19. Morrato EH, Nicol GE, Maahs D, et al: Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics and Adolescent Medicine 164:344-351, 2010
20. Kryzhanovskaya L, Schulz SC, McDougle C, et al: Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 48:60-70, 2009
21. Findling RL, McNamara NK, Youngstrom EA, et al: A prospective, open-label trial of olanzapine in adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 42:170-175, 2003
22. Almandil NB, Liu Y, Murray ML, et al: Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatric Drugs 15:139-150, 2013
23. Ben Amor L: Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. Journal of Affective Disorders 138(suppl):S22-S30, 2012
24. Rummel-Kluge C, Komossa K, Schwarz S, et al: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 123:225-233, 2010
25. Gallini A, Donohue JM, Huskamp HA: Diffusion of antipsychotics in the US and French markets, 1998-2008. Psychiatric Services 64:680-687, 2013
26. Gerhard T: Second Generation Antipsychotics and Risk of Type 2 Diabetes in Publicly Insured Children and Adolescents. New Brunswick, NJ, Rutgers University, Centers for Education and Research on Therapeutics. Available at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM272847.pdf
27. Morrato EH, Newcomer JW, Kamat S, et al: Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32:1037-1042, 2009
28. Bisgaier J, Rhodes KV: Auditing access to specialty care for children with public insurance. New England Journal of Medicine 364:2324-2333, 2011
29. Rabi DM, Edwards AL, Southern DA, et al: Association of socioeconomic status with diabetes prevalence and utilization of diabetes care services. BMC Health Services Research 6:124, 2006
30. Moeller KE, Rigler SK, Mayorga A, et al: Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance. Schizophrenia Research 126:117-123, 2011
31. Morrato EH, Druss BG, Hartung DM, et al: Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users. Pharmacoepidemiology and Drug Safety 20:66-75, 2011
32. Colton CW, Manderscheid RW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 3:A42, 2006
33. Druss BG, Zhao L, Von Esenwein S, et al: Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Medical Care 49:599-604, 2011
34. Buckley PF, Miller DD, Singer B, et al: Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophrenia Research 79:281-288, 2005
35. Khan AY, Shaikh MR, Ablah E: To examine the extent of compliance to the proposed monitoring protocol among practicing psychiatrists for second generation antipsychotics. Journal of the Pakistan Medical Association 60:446-450, 2010
36. Cabana MD, Rand CS, Powe NR, et al: Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282:1458-1465, 1999
37. Mangurian C, Giwa F, Shumway M, et al: Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication. Psychiatric Services 64:597-599, 2013
38. Ogden CL, Carroll MD, Kit BK, et al: Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 307:483-490, 2012
39. Dabelea D, Mayer-Davis EJ, Saydah S, et al: Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 311:1778-1786, 2014
40. Skinner AC, Skelton JA: Prevalence and trends in obesity and severe obesity among children in the United States, 1999-2012. JAMA Pediatrics 168:561-566, 2014